FNCHQ 8-K
Finch Therapeutics Group, Inc. (FNCHQ)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 10, 2022, Finch Therapeutics Group, Inc. (the “Company”) held its Annual Meeting of Stockholders. A total of 36,785,341 shares of the Company’s common stock were present electronically or by proxy at the meeting, representing approximately 77.35% of the Company’s outstanding common stock as of the April 11, 2022 record date. The following are the voting results for the proposals considered and voted upon at the meeting, all of which were described in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on April 26, 2022.
Item 1: To elect three nominees Class I directors: Domenic Ferrante, Nicholas Haft and Samuel A. Hamood, each to hold office until the Annual Meeting of Stockholders in 2025.
Nominee |
Votes For |
Votes Withheld |
Broker Non-Votes |
Domenic Ferrante |
26,834,882 |
1,962,749 |
7,987,710 |
Nicholas Haft |
26,900,076 |
1,897,555 |
7,987,710 |
Samuel A. Hamood |
28,790,064 |
7,567 |
7,987,710 |
Item 2: To ratify the selection by the audit committee of the board of directors of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022.
Votes For |
Votes Against |
Abstentions |
Broker Non-Votes |
36,759,831 |
20,585 |
4,925 |
0 |
Based on the foregoing votes, each of Messrs. Ferrante, Haft and Hamood was elected as a Class I director and Item 2 was approved.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
FINCH THERAPEUTICS GROUP, INC. |
|
|
|
|
Date: |
June 16, 2022 |
By: |
/s/ Mark Smith |
|
|
|
Mark Smith, Ph.D. |